Citi initiated coverage of Voyager Therapeutics (VYGR) with a Buy rating and $12 price target Voyager is an early clinical-staged biotech developing therapies for the treatment of neurological disorders, the analyst tells investors in a research note. The firm sees “meaningful value” in Voyager’s platform from both a clinical and business development perspective. The company’s anti-tau antibody, VY7523, is currently in a Phase 1a for healthy volunteers with data expected in the first half of 2025, Citi points out.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager upgraded, HP downgraded: Wall Street’s top analyst calls
- Voyager rises after upgrade, Applied plunges after CRL: Morning Movers
- Wedbush upgrades Voyager to Outperform on pipeline progress
- Voyager Therapeutics assumed with Outperform from Neutral at Wedbush
- Voyager Therapeutics selects VY1706 for program in Alzheimer’s Disease